Healthcare Industry News: Nabi Biopharmaceuticals
News Release - March 6, 2006
Replidyne Names Mark Smith Chief Financial OfficerLOUISVILLE, Colo., March 6 (HSMN NewsFeed) -- Replidyne, Inc., a privately held biopharmaceutical company focused on the discovery and development of new anti-infective drugs, announced today that it has appointed Mark Smith as its Chief Financial Officer.
Mr. Smith joins Replidyne from Nabi Biopharmaceuticals where he has served as Senior Vice President, Finance, Treasurer and Chief Financial Officer for the past five years. He also served as Vice President, Finance and Senior Director, Finance and Chief Accounting Officer since joining Nabi in 1999. Prior to joining Nabi, Mr. Smith served as Vice President of Finance and Administration and Chief Financial Officer of Neuromedical Systems, Inc., where he played a leadership role in that company's strategic restructuring and sale. Prior to joining Neuromedical Systems, Mr. Smith served in various financial executive capacities at Genzyme Corporation and Genetrix, Inc. Before joining Genetrix, Mr. Smith practiced with the accounting firm of Price Waterhouse in both Australia and the United States. Mr. Smith received his Bachelor of Arts degree from Canberra College of Advanced Education. He is a CPA and a member of the Institute of Chartered Accountants in Australia.
"We are delighted that Mark has joined Replidyne as our Chief Financial Officer. His extensive accounting and finance background, as well as his experience in the anti-infective area, make him an outstanding addition to Replidyne's management team," said Kenneth J. Collins, President and CEO of Replidyne. "We expect Mark to make major contributions to finance, operations and the strategic direction of the Company as we expand our pipeline and move our products toward commercialization."
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. Replidyne's New Drug Application (NDA) for its lead product, faropenem medoxomil, was recently accepted for standard review by the FDA. Replidyne and Forest Laboratories also recently entered into an agreement for the commercialization, development and distribution of faropenem medoxomil in the United States. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other current development programs include higher dose/shorter course therapy, additional indications for adults, and a pediatric formulation of faropenem medoxomil. The Company's pipeline also includes a topical anti-bacterial product, REP8839, which has a novel mechanism of action for addressing the major challenge of methicillin-resistant Staphylococcus aureus (MRSA). Replidyne also has discovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. For additional information about Replidyne, Inc., please visit: www.replidyne.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.